A case-control study of Fruquintinib combined with anti-PD-1 versus PD-1 in the treatment of metastatic colon cancer (a randomized, open-label phase II clinical trial)

ABSTRACT: Interventions: Fruquintinib combined with anti-PD-1 group:Fruquintinib combined with Pembrolizumab;Anti-PD-1 group:Pembrolizumab Primary outcome(s): The level of adverse reactions in patients;Patient quality of life score Study Design: Parallel

DISEASE(S): Colorectal Cancer

PROVIDER: 2759471 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR